Investors will be expecting an update on the sale of Elan when the drug company reports its second-quarter results on Wednesday.
The company is not expected to entertain any bids until after the results, but speculation has swirled around the company since Royalty Pharma abandoned its hostile takeover approach in June, leaving the way open for an auction process. In the meantime, there has been lots of activity in the stock as institutional shareholders trade...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team